Furoscix
Payments companies reported to CMS as associated with Furoscix. "Associated with" is CMS's wording: it links a payment to a product without saying the money was spent on it.
By year
Payments reported as associated with Furoscix, per program year, as reported to CMS.
Who makes it
Specialties most often involved
Where the associated payments went, by the receiving clinician's specialty.
Clinicians most associated with Furoscix
These are the largest totals companies reported as associated with Furoscix. They are typically speaking or consulting arrangements, which companies must report by law; appearing here is not evidence of anything improper.
| Clinician | Location | Specialty | Associated payments (2023-2025) |
|---|---|---|---|
| Hunter Champion | Columbus, GA | Cardiovascular Disease | $174,752.56 |
| William Abraham | Columbus, OH | Advanced Heart Failure and Transplant Cardiology | $133,127.44 |
| Daniel Bensimhon | Greensboro, NC | Advanced Heart Failure and Transplant Cardiology | $105,372.76 |
| Georges Chahoud | Saint Louis, MO | Cardiovascular Disease | $71,747.84 |
| Vamsi Krishna | Kyle, TX | Interventional Cardiology | $67,248.38 |
| Gautam Shah | Fairview Park, OH | Cardiovascular Disease | $64,263.05 |
| Benjamin Kalsmith | Pgh, PA | Cardiovascular Disease | $62,915.96 |
| Erika Feller | Baltimore, MD | Cardiovascular Disease | $61,016.99 |
| Rigved Tadwalkar | Santa Monica, CA | Cardiovascular Disease | $58,750.13 |
| Amin Yehya | Norfolk, VA | Advanced Heart Failure and Transplant Cardiology | $53,786.20 |
Prescribed Furoscix?
See what its makers reported for your doctor. Two steps, private, no account.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.